cetuximab + cisplatin + doxorubicin + cyclophosphamide

Cetuximab + cisplatin + doxorubicin + cyclophosphamide is a multi-agent chemotherapy regimen combining four distinct anticancer drugs, each with different mechanisms of action. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting downstream signaling pathways involved in cell proliferation and survival. Cisplatin is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to apoptosis. Doxorubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, causing DNA damage and cell death. Cyclophosphamide is an alkylating agent that crosslinks DNA strands, preventing replication and transcription. This combination aims to maximize antitumor efficacy through synergistic effects on multiple cellular targets and pathways[1][2][3][5][6].

Brand names

Erbitux (for cetuximab)Platinol (for cisplatin)Adriamycin (for doxorubicin)Cytoxan (for cyclophosphamide)